This past year has seen more gene therapies approved by the FDA than the previous five years combined, and almost triple the number of clinical trials in gene therapy have been initiated in H1 of 2023 compared to the same time frame in the previous year. 

To maximize the value of your late-stage gene therapy assets, the 7^th Gene Therapy for Rare Disorders Summit returned to tackle head-on the significant clinical, manufacturing, regulatory, and commercial challenges facing gene therapy programs. 

Bringing together key figures from industry, regulatory bodies, patient non-profits, payers, and key service providers, this was the field’s foremost meeting for collectively progressing rare gene therapy programs into and through the clinic.  

We joined together over 200 peers from leading biopharma companies with direct experience in driving gene therapies through the clinic and into the market.